Bevacizumab plus chemotherapy for ovarian cancer

被引：0
|
作者：
Ozkan, Judy
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(14)70142-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E202 / E202
页数：1
相关论文
共 50 条
  • [1] THROMBOEMBOLIC EVENTS ASSOCIATED WITH BEVACIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH OVARIAN CANCER
    Takasaki, K.
    Miyamoto, M.
    Takano, M.
    Soyama, H.
    Aoyama, T.
    Matsuura, H.
    Kato, K.
    Sakamoto, T.
    Oyaizu, M.
    Iwahashi, H.
    Ishibashi, H.
    Yoshikawa, T.
    Huruya, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 850 - 850
  • [2] Intraperitoneal chemotherapy without bevacizumab versus intravenous chemotherapy plus bevacizumab as frontline therapy in advanced ovarian cancer
    Ting, Wan Hua Stella
    Wang, Hsiao-Feng
    Chen, Hui-Hua
    Sun, Hsu-Dong
    Wei, Ming-Chow
    Hsiao, Sheng-Mou
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A205 - A206
  • [3] Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer
    Khanmammadov, Nijat
    Dogan, Izzet
    Okay, Necla Simay
    Azizy, Abdulmunir
    Saip, Pinar
    Aydiner, Adnan
    MEDICINE, 2024, 103 (01)
  • [4] Bevacizumab plus chemotherapy promising for colorectal cancer
    Lindsey, H
    LANCET ONCOLOGY, 2003, 4 (03): : 137 - 137
  • [5] Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
    Hamilton, Gerhard
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2157 - 2160
  • [6] Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.
    Khanmammadov, Nijat
    Dogan, Izzet
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] The role of bevacizumab plus front-line chemotherapy in patients with malignant ascites of ovarian cancer
    Nikolaou, M.
    Ziras, N.
    Athanasiadis, I.
    Ardavanis, A.
    Vaslamatzis, M.
    Kentepozidis, N.
    Makrantonakis, P.
    Christopoulou, A. N.
    Michalaki, V.
    Polizos, A.
    Emmanouilidis, C.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
    Cai, Hongfu
    Fang, Ling
    Lin, Jingwen
    Zheng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [9] Bevacizumab and weekly topotecan as salvage chemotherapy for ovarian cancer
    Scamon, L. G.
    Richardson, D. L.
    Hurt, J. D.
    Fowler, J. M.
    O'Malley, D. M.
    Copeland, L. J.
    Cohn, D. E.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S57 - S57
  • [10] Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy
    Ventriglia, Jole
    Paciolla, Immacolata
    Pisano, Carmela
    Tambaro, Rosa
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Attademo, Laura
    Arenare, Laura
    Spina, Anna
    Russo, Daniela
    Califano, Daniela
    Losito, Nunzia Simona
    Setola, Sergio Venanzio
    Franzese, Elisena
    De Vita, Ferdinando
    Orditura, Michele
    Pignata, Sandro
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 110 - 113
12345